Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte-macrophage colony-stimulating factor gene transfer

Cancer Gene Therapy

Volumn 7, Issue 2, 2000, Pages 177-186

  Cao, Xuetao ^a   Huang, Xin ^a   Ju, Dian Wen ^a   Zhang, Weiping ^a   Hamada, Hirofumi ^b   Wang, Jianli ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b Foundation for the Promotion of Cancer Research (Japan)   (Japan)

Author keywords

Adenovirus; Antigen presenting cells; Antitumoral immunity; Cytosine deaminase; Granulocyte macrophage colony stimulating factor; Stem cell factor; Suicide gene therapy

Indexed keywords

CYTOSINE DEAMINASE; FLUCYTOSINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; INTERLEUKIN 4; MESSENGER RNA; STEM CELL FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ADENOVIRUS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; COLON ADENOCARCINOMA; CONTROLLED STUDY; CYTOKINE RELEASE; CYTOTOXIC T LYMPHOCYTE; FEMALE; GENE THERAPY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE;

ADENOVIRIDAE; ANIMALIA; ESCHERICHIA COLI; MURINAE;

EID: 0034032940     PISSN: 09291903     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.cgt.7700114     Document Type: Article

References (61)

1. Deonarain MP, Spooner RA, Epenetos AA. Genetic delivery of enzymes for cancer therapy. Gene Ther. 1995; 2:235-244.
2. Mullen CA. Metabolic suicide genes in gene therapy. Pharmacol Ther. 1994;63:199-207.
3. Tiberghien P. Use of suicide genes in gene therapy. J Leukocyte Biol. 1994;56:203-209.
4. Marcel T, Grausz JD. The TMC Worldwide Gene Therapy Enrollment Report, end 1996. Hum Gene Ther. 1997;8: 775-800.
5. Barba D, Hardin J, Sadelan M, Gage FH. Development of antitumor immunity following thymidine kinase-mediated killing of experimental brain tumors. Proc Natl Acad Sci USA. 1994;91:4348-4351.
6. Izquierdo M, Martin V, De Felipe P, et al. Human malignant brain tumor response to herpes simplex thymidine kinase HSVtk/ganciclovir gene therapy. Gene Ther. 1996-3:491-495.
7. Austin EA, Huber BE. A first step in development of gene therapy for colorectal carcinoma cloning: sequencing and expression of Escherichia coli cytosine deaminase. Mol Pharmacol. 1992;43:380-387.
8. Huber BE, Austin EA, Good SS, Knick VC, Tibbels S, Richards CA. In vivo antitumor activity of 5-fluorocytosine on human colorectal carcinoma cells genetically modified to express cytosine deaminase. Cancer Res. 1993;53:4619-4626.
9. Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorourail in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc Natl Acad Sci USA. 1994;91:8302-8306.
10. Hirschowitz EA, Ohwada A, Pascal WR, Russi TJ, Crystal RG. In vivo adenovirus-mediated gene transfer of the Escherichia coli cytosine deaminase gene to human colon carcinoma-derived tumors induces chemosensitivity to 5-fluorocytosine. Hum Gene Ther. 1995;6:1055-1063.
11. Mullen CA, Coale MM, Lowe R, Blaese RM. Tumors expressing the cytosine deaminase suicide gene can be eliminated in vivo with 5 fluorocytosine and induce protective immunity to wild type tumor. Cancer Res. 1994;54: 1503-1506.
12. Szala S, Missol E, Sochanik A, Strozyk M. The use of cationic liposomes DC CHOL/DOPE and DDAB/DOPE for direct transfer of Escherichia coli cytosine deaminase gene into growing melanoma tumors. Gene Ther. 1996;3: 1026-1031.
13. Ramesh R, Marrogi AJ, Munshi A, Abboud CN, Freeman SM. In vivo analysis of the "bystander effect": a cytokine cascade. Exp Hematol. 1996;24:829-838.
14. Castleden SA, Chong H, Garcia-Ribas I, et al. A family of bicistronic vectors to enhance both local and systemic antitumor effects of HSVtk or cytokine expression in a murine melanoma model. Hum Gene Ther. 1997;8:2087-2102.
15. Coll J-L, Mesnil M, Lefebvre M-F, Lancon A, Favrot MC. Long-term survival of immunocompetent rats with intraperitoneal colon carcinoma tumors using herpes simplex thymidine kinase/ganciclovir and IL-2 treatments. Gene Ther. 1997;4:1160-1166.
16. Felzmann T, Ramsey WJ, Blaese RM. Characterization of the antitumor immune response generated by treatment of murine tumors with recombinant adenoviruses expressing HSVtk, IL-2, IL-6, or B7-1. Gene Ther. 1997;4:1322-1329.
17. Cao X, Zhang W, Ma S, Zhang M, Wang J, Ye T. Enhanced antitumor effects of tumor antigen-pulsed dendritic cells by their transfection with GM-CSF gene. Sci China Ser C. 1997;40:539-545.
18. Abe J, Wakimoto H, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. Antitumor effect induced by granulocyte/ macrophage colony-stimulating factor gene-modified tumor vaccination: comparison of adenovirus-and retrovirus-mediated genetic transduction, J Cancer Res Clin Oncol. 1995;121:587-593.
19. Kanai F, Lan KH, Shiratori Y, et al. In vivo gene therapy for a fetoprotein-producing hepatocellular carcinoma by adenovirus-mediated transfer of cytosine deaminase gene. Cancer Res. 1997;57:461-465.
20. Chen W, Qin H, Chesebro B, Cheever MA. Identification of a gag-encoded cytotoxic T-lymphocyte epitope from FBL-3 leukemia shared by Friend, Moloney, and Rauscher murine leukemia virus-induced tumors. J Virol. 1996;170: 773-778.
21. Ju DW, Cao X, Acres B. Intratumoral injection of GM-CSF gene encoded recombinant vaccinia virus elicits a potent antitumor response in a murine melanoma model. Cancer Gene Ther. 1997;4:139-144.
22. Barinaga M. Gene therapy for clogged arteries passes test in pigs. Science. 1994;265:738-741.
23. Dilber MS, Abedi MR, Bjorkstrand B, et al. Suicide gene therapy for plasma cell tumors. Blood. 1996;88:2192-2200.
24. Harrell RL, Rajanayagam S, Doanes AM, et al. Inhibition of vascular smooth muscle cell proliferation and neointimal accumulation by adenovirus-mediated gene transfer of cytosine deaminase. Circulation. 1997;96:621-627.
25. Kwong YL, Chen SH, Kosai K, Finegold MJ, Woo SL. Adenoviral-mediated suicide gene therapy for hepatic metastases of breast cancer. Cancer Gene Ther. 1996;3: 339-344.
26. Muyombwe A, Olivier M, Ouellette M, Papadopoulou B. Selective killing of Leishmania amastigotes expressing a thymidine kinase suicide gene. Exp Parasitol. 1997;85:35-42.
27. Rogers RP, Ge JQ, Holley-Guthrie E, et al. Killing Epstein-Barr virus-positive B lymphocytes by gene therapy: comparing the efficacy of cytosine deaminase and herpes simplex virus thymidine kinase. Hum Gene Ther. 1996;7:2235-2245.
28. Dong Y, Wen P, Manome Y, et al. In vivo replication-deficient adenovirus vector-mediated transduction of the cytosine deaminase gene sensitizes glioma cells to 5-fluorocytosine. Hum Gene Ther. 1996;7:713-720.
29. Evoy D, Hirschowitz EA, Naama HA, et al. In vivo adenoviral-mediated gene transfer in the treatment of pancreatic cancer. J Surg Res. 1997;69:226-231.
30. Li Z, Shanmugam N, Katayose D, et al. Enzyme/prodrug gene therapy approach for breast cancer using a recombinant adenovirus expressing Escherichia coli cytosine deaminase. Cancer Gene Ther. 1997;4:113-117.
31. Crystal RG, Hirschowitz E, Lieberman M, et al. Phase I study of direct administration of a replication-deficient adenovirus vector containing the E. coli cytosine deaminase gene to metastatic colon carcinoma of the liver in association with the oral administration of the pro-drug 5-fluorocytosine. Hum Gene Ther. 1997;8:985-1001.
32. Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV 1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum Gene Ther. 1997;8:73-85.
33. Harris JD, Gutierrez AA, Hurst HC, Sokora K, Lemoine NR. Gene therapy for cancer using tumor-specific prodrug activation. Gene Ther. 1994;1:170-175.
34. Ring CJ, Harris JD, Hurst HC, Lemoine NR. Suicide gene expression induced in tumour cells transduced with recombinant adenoviral retroviral and plasmid vectors containing the ERBB2 promoter. Gene Ther. 1996;3:1094-1103.
35. Richards CA, Austin EA, Huber BE. Transcriptional regulatory sequences of carcinoembryonic antigen: identification and use with cytosine deaminase for tumor-specific gene therapy. Hum Gene Ther. 1995;6:881-893.
36. Klatzmann D. Gene therapy for metastatic malignant melanoma: evaluation of tolerance to an intratumoral injection of cells producing recombinant retroviruses carrying the herpes simplex virus type 1 thymidine kinase gene, to be followed by ganciclovir administration. Hum Gene Ther. 1996;7:255-267.
37. Paillard F. Bystander effects in enzyme/prodrug gene therapy. Hum Gene Ther. 1997;8:1733-1736.
38. Pitts JD. Cancer gene therapy: a bystander effect using the gap junction pathway. Mol Carcinog. 1994;11:127-130.
39. Benedetti S, Dimeco F, Polio B, et al. Limited efficacy of the HSV-TK/GCV system for gene therapy of malignant gliomas and perspectives for the combined transduction of the interleukin-4 gene. Hum Gene Ther. 1997;8:1345-1353.
40. Ishii-Morita H, Agbaria R, Mullen CA, et al. Mechanism of "bystander effect" killing in the herpes simplex thymidine kinase gene therapy model of cancer treatment. Gene Ther. 1997;4:244-251.
41. Denning C, Pitts JD. Bystander effects of different enzyme-prodrug systems for cancer gene therapy depend on different pathways for intercellular transfer of toxic metabolites, a factor that will govern clinical choice of appropriate regimes. Hum Gene Ther. 1997;8:1825-1835.
42. Bi W, Kim YG, Feliciano ES, et al. An HSV tk-mediated local and distant antitumor bystander effect in tumors of head and neck origin in athymic mice. Cancer Gene Ther. 1997;4:246-252.
43. Consalvo M, Mullen CA, Modesti A, et al. 5-Fluorocytosine-induced eradication of murine adenocarcinomas engineered to express the cytosine deaminase suicide gene requires host immune competence and leaves an efficient memory. J Immunol. 1995;154:5302-5312.
44. Freeman SM, Ramesh R, Marrogi AJ. Immune system in suicide-gene therapy. Lancet. 1997;49:2-3.
45. Kianmanesh AR, Perrin H, Panis Y, et al. A "distant" bystander effect of suicide gene therapy regression of nontransduced tumors together with a distant transduced tumor. Hum Gene Ther. 1997;8:1807-1814.
46. Chen SH, Chen XH, Wang Y, et al. Combination gene therapy for liver metastasis of colon carcinoma in vivo. Proc Natl Acad Sci USA. 1995;92:2577-2581.
47. Chen SH, Kosai K, Xu B, et al. Combination suicide and cytokine gene therapy for hepatic metastases of colon carcinoma: sustained antitumor immunity prolongs animal survival. Cancer Res. 1996;56:3758-3762.
48. Santodonato L, Ferrantini M, Gabriele L, et al. Cure of mice with established metastatic Friend leukemia cell tumors by a combined therapy with tumor cells expressing both interferon-α1 and herpes simplex thymidine kinase followed by ganciclovir. Hum Gene Ther. 1996;7:1-10.
49. Ju DW, Wang B, Cao X. Adenovirus-mediated combination suicide gene and interleukin 2 gene therapy for the treatment of established tumor and induction of antitumor immunity. J Cancer Res Clin Oncol. 1998;124:683-689.
50. Cao X, Ju DW, Tao Q, et al. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit a more potent antitumor response in tumor-bearing mice. Gene Ther. 1998;5:1130-1136.
51. Mullen CA, Petropoulos D, Lowe RM. Treatment of microscopic pulmonary metastases with recombinant autologous tumor vaccine expressing interleukin 6 and Escherichia coli cytosine deaminase suicide genes. Cancer Res. 1996;56:1361-1366.
52. Morse MA, Zhou LJ, Tedder TF, Lyerly HK, Smith C. Generation of dendritic cells in vitro from peripheral blood mononuclear cells with granulocyte-macrophage-colony-stimulating factor, interleukin-4, and tumor necrosis factor-α for use in cancer immunotherapy. Ann Surg. 1997;226:6-16.
53. O'Doherty U, Ignatius R, Bhardwaj N, Pope M. Generation of monocyte-derived dendritic cells from precursors in rhesus macaque blood. J Immunol Methods. 1997;207:185-194.
54. Toujas L, Delcros JG, Diez E, et al. Human monocyte-derived macrophages and dendritic cells are comparably effective in vitro in presenting HLA class I-restricted exogenous peptides. Immunology. 1997;91:635-642.
55. Cao X, Chen G, Zhang W, Yu Y, Ye T. Enhanced efficacy of a combination of IL-2 gene-and IL-6 gene-transfected tumor cells in the treatment of established metastatic tumors. Gene Ther. 1996;3:421-426.
56. + progenitors in bone marrow and cord blood. Br J Haematol. 1996;93:258-264.
57. Santiago-Schwarz F, Rappa DA, Laky K, Carsons SE. Stem cell factor augments tumor necrosis factor-granulocyte-macrophage colony-stimulating factor-mediated dendritic cell hematopoiesis. Stem Cells. 1995;13:186-197.
58. Armstrong CA, Botella R, Galloway TH, et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res. 1995;56: 2191-2198.
59. Gabilovich DI, Nadaf S, Corak J, Berzofsky JA, Carbone DP. Dendritic cells in antitumor immune response: dendritic cells grown from bone marrow precursors but not mature DC from tumor-bearing mice are effective antigen carriers in the therapy of established tumors. Cell Immunol. 1996;170:111-119.
60. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte-macrophage colony-stimulating factor. J Exp Med. 1992;176:1693-1702.
61. Lee C-K, Wu S, Ciernik IF, et al. Genetic immunotherapy of established tumors with adenovirus-murine granulocyte-macrophage colony-stimulating factor. Hum Gene Ther. 1997;8:187-193.